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IP-10 Kinetics in the First Week of 
Therapy are Strongly Associated 
with Bacteriological Confirmation 
of Tuberculosis Diagnosis in HIV-
Infected Patients
Alberto L. García-Basteiro1,2,3, Edson Mambuque1, Alice den Hertog4,5, Belén Saavedra1, 
Inocencia Cuamba1, Laura Oliveras  1,2, Silvia Blanco1,2, Helder Bulo1, Joe Brew1,2, Luis E. 
Cuevas  6, Frank Cobelens3, Augusto Nhabomba1 & Richard Anthony5
Simple effective tools to monitor the long treatment of tuberculosis (TB) are lacking. Easily measured 
host derived biomarkers have been identified but need to be validated in larger studies and different 
population groups. Here we investigate the early response in IP-10 levels (between day 0 and day 7 of 
TB therapy) to identify bacteriological status at diagnosis among 127 HIV-infected patients starting TB 
treatment. All participants were then classified as responding or not responding to treatment blindly 
using a previously described IP-10 kinetic algorithm. There were 77 bacteriologically confirmed cases 
and 41 Xpert MTB/RIF® and culture negative cases. Most participants had a measurable decline in 
IP-10 during the first 7 days of therapy. Bacteriologically confirmed cases were more likely to have high 
IP-10 levels at D0 and had a steeper decline than clinically diagnosed cases (mean decline difference 
2231 pg/dl, 95% CI: 897–3566, p = 0.0013). Bacteriologically confirmed cases were more likely to have 
a measurable decline in IP-10 at day 7 than clinically diagnosed cases (48/77 (62.3%) vs 13/41 (31.7%), 
p < 0.001). This study confirms the association between a decrease in IP-10 levels during the first week 
of treatment and a bacteriological confirmation at diagnosis in a large cohort of HIV positive patients.
Tuberculosis (TB) remains a primary global health concern but the tools to diagnose and manage patients on 
long and complex treatment regimens are suboptimal. The World Health Organization (WHO) estimated that 
there were around 10.4 million new cases of TB in 20151 but only two thirds of these were actually reported to the 
health authorities. Furthermore, only 57% and 15% of notified incident pulmonary and extra pulmonary TB cases 
respectively are ever bacteriologically confirmed1. Among this large group of clinically diagnosed patients, there 
is likely a proportion of cases who initiate treatment without having TB2,3, or receive first-line therapy but have 
drug resistant TB (DR-TB)4. Providing TB treatment to a patient without TB risks drug-related toxicity and delays 
the diagnosis of the true cause of symptoms. First-line treatment given to a patient with DR-TB could further 
select resistant mutants to the remaining active drugs and delays proper treatment. Thus, assays to confirm a TB 
diagnosis and to monitor TB treatment are needed for the appropriate management of patients5.
The methods routinely used to monitor TB treatment are sputum or culture conversion, resolution of radio-
logical signs or clinical improvement6, which have considerable limitations. Sputum smear lacks sensitivity and is 
unable to document the viability of the bacilli. Culture is more sensitive but provides results after several weeks, 
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while radiology and clinical improvement have low specificity. Under programmatic conditions sputum and cul-
ture conversion are performed at month 2 of treatment. Clinical improvement suggests the initial diagnosis was 
correct, although the poor specificity of symptoms and the coexistence of comorbidities make clinical monitoring 
relatively unreliable. Radiological improvement lacks specificity and is slow, requiring expert interpretation and, 
in many cases, might only become obvious after several months.
In recent years, several assays and strategies have been evaluated to monitor TB treatment. These include, 
sputum based strategies (early bactericidal activity (EBA) methods, new nucelid acid amplification tests (NAAT) 
or whole blood bactericidal activity), lung function, radiological markers (including X-Ray scores, ultra-
sound or PET/Computerized Tomography), transcriptomic profiling and host immune biomarkers (including 
interferon-gamma release assays [IGRAs])6.
The use of measurable host immune biomarkers has been reported to correlate with disease severity and could 
potentially be used at point of care7. These include acute phase proteins, cytokines, subsets of T-lymphocytes or 
matrix metalloproteinases activated from tissue destruction6,8. One of the most promising molecules whose kinet-
ics has been associated with treatment response is IP-10 (CXCL-10), a pro-inflammatory chemokine involved in 
several pathological processes. IP-10 participates in the recruitment of activated T cells, macrophages and Natural 
Killer (NK) cells9. Increased serum IP-10 concentrations are found in patients with cancer, autoimmune diseases, 
active infections10 and active and latent TB11–14. Although most studies exploring the role of IP-10 to monitor TB 
treatment had small sample sizes (a few dozens in most cases), there seems to be a correlation between the time of 
sputum conversion and a decrease in IP-10 levels, both in fresh and dried plasma samples15,16.
Significant decreases in IP-10 are correlated with a good treatment response at month 217,18 and correlate with 
sputum conversion19 and treatment outcome20. A pilot study in Nigeria and Nepal showed that the likelihood 
of culture positivity at diagnosis could be predicted through a change from high to low IP-10 plasma levels after 
seven days of treatment21.
We sought to validate this prediction in an HIV-infected population, which due to impaired immunity might 
show altered IP-10 responses. We investigated if changes in the kinetics of circulating IP-10 in the first week of 
therapy are associated with bacteriological confirmation of TB among adult HIV infected patients starting TB 
treatment. As a secondary objective we explored the relationship between serum IP-10 kinetics and treatment 
outcomes.
Methods
Study setting. The study was conducted in Manhiça district, Southern Mozambique, by the Centro de 
Investigação em Saude de Manhiça (CISM). Manhiça has approximately 178,000 inhabitants and 39,000 house-
holds22 and 39.9% of 18–47 year old adults have HIV23. TB notification rates in Manhiça have been rising since 
the late 1990s1,24,25 and TB mortality during treatment is very high, especially among HIV infected individu-
als26. Multidrug-resistant (MDR) TB prevalence in the district is 4% and 15% among new and retreatment cases, 
respectively27.
TB treatment for new patients is offered free of charge at all district health units, consisting of 6-month fixed 
dose combinations (isoniazid, rifampicin, ethambutol and pyrazinamide) which are replenished weekly. The ini-
tial diagnostic test used for HIV-infected patients with symptoms of TB is Xpert MTB/RIF®.
Study design and procedures. Adults attending the HIV clinic at Manhiça Health Centre (MHC) with 
presumptive TB were consecutively enrolled in the study from August 2015 to March 2016. A presumptive TB 
case was defined as an adult ≥18 years old presenting with cough and/or weight loss and/or fever and/or night 
sweats of any duration. Potential participants were asked to sign an informed consent before enrolment. Inclusion 
criteria included a presumptive diagnosis of TB and documented HIV infection. Patients who had received TB 
treatment in the previous 6 months were excluded.
All participants with a TB diagnosis (regardless of bacteriological confirmation) were referred to the National 
TB Program (NTP) office at MHC to start treatment. Blood samples were collected before TB treatment initiation 
(D0), and on days 7 (D7) and 60 (D60). A window of +3 days (D7-D10) was permitted for the second visit and 
±5 days for the final visit (D55-D65).
Patients were instructed to provide two sputum samples the day after first attendance to confirm the diagnosis 
of TB (as per national guidelines). Patients not providing sputum samples the next day were asked to provide a 
sputum sample on the spot before obtaining the blood sample and before initiating anti-TB treatment (ATT).
Laboratory procedures. Five ml of blood were collected at D0 for CD4 counts and 2–5 ml on D7 and D60 
using vacutainer tubes without anti-coagulant and transported to the local immunology laboratory for centrif-
ugation at 1,500 rpm for 15 minutes. Sera were stored at −20 °C for maximum 4 weeks before IP-10 testing was 
performed.
Serum samples were tested using a commercial IP-10 ELISA (Becton Dickinson and Company, New Jersey, 
USA, - Human IP-10 ELISA Set. Cat. No. 550926) at 1:100 and 1:1000 fold dilution, following the manufacturer’s 
instructions. A standard curve was produced using freshly prepared serial dilutions of the kit’s reference standard 
from 500 pg/ml to 7.8 pg/ml.
All sputum samples were tested using Xpert MTB/RIF, liquid culture (BACTECTM MGITTM 960) and light 
smear microscopy (Ziehl Neelsen stain).
Definitions and hypothesis. A TB case was defined as a person starting ATT, either microbiologically 
confirmed (positive light smear microscopy, Xpert MTB/RIF or culture) or clinically diagnosed as per WHO 
guidelines28. Treatment outcome was classified as cured, completed, failed, died, lost to follow up or not evaluated. 
Treatment success was defined as the sum of the outcomes of cured and completed.
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We developed an algorithm to predict the expected TB treatment response prior to reviewing the observed 
diagnostic results and outcomes in the follow up. The outcomes predicted by the algorithm were blinded to all 
microbiological information and based only on the observed IP-10 kinetics on D0, D7 and D60 and on find-
ings by den Hertog et al. (Fig. 1)21. Briefly, a D0 IP-10 > 1081 pg/ml followed by a decrease ≥300 pg/ml at D7 
would predict a good ATT response. A D0 IP-10 > 1081 pg/ml without a significant IP-10 decrease (i.e. a change 
<300 pg/ml) on D7 would predict a poor TB treatment response (due for example to DR-TB, a disease other 
than TB, or lack of exposure to ATT, e.g. due to non-compliance or poor absorption). D0 IP-10 concentrations 
<1081 pg/ml were interpreted as no evidence of TB, regardless of the IP-10 value at D7.
All participants were then classified blindly using the IP-10 kinetic algorithm. We hypothesized that there 
would be a higher proportion of bacteriologically confirmed cases among those predicted to have “good IP-10 
response” (Fig. 1).
Data collection and analysis. Questionnaires were double entered into an electronic database. Data was 
then exported for analysis. ATT adherence was collected at D7 and D60 through self-reporting. Treatment out-
comes were collected from the NTP registers at month 6. All deaths were confirmed through the CISM demo-
graphic surveillance system which covers nearly 100% of the district population. Data were analysed using STATA 
version 13 and R version 3.3.1 (Stata Corp, College Station TX, USA). Pearson’s Chi squared and Fishers’ exact 
tests were used to analyse the association between laboratory confirmation at diagnosis and IP-10 kinetics at D7 
and D60 and Student’s T-test to compare means between different groups.
Ethics statement. The study was approved by CISM’s Internal Scientific Committee, CISM Institutional 
Bioethics Committee for Health and the National Bioethics Committee of Mozambique (Reference 118/
CNBS/14). All individuals provided written informed consent to participate. The study methods were carried 
out in accordance with the relevant guidelines and regulations established by the National Bioethics Committee 
at the Ministry of Health.
Data availability statement. The datasets generated during the current study are kept at the data center 
of CISM. An anonymized version of the dataset can be made available upon request to CISM’s Internal Scientific 
Committee (Email: cci@manhica.net).
Results
A total of 127 patients with a mean (SD) age of 37.1 (10.1) years of age were recruited. Seventy-four (58.3%) were 
male and 80 (63.0%) had bacteriologically confirmed TB. Of these, 4 had rpoB gene mutations by Xpert® MTB/
RIF, although only 2 of these could be confirmed as MDR by Minimum Inhibitory Concentration (MIC) testing 
in liquid culture. Seven (9.2%) were mono-resistant to isoniazid by MIC. Over one third of the patients (34.3%) 
had CD4 counts <100 at recruitment. Twenty-eight (33%) participants died during the course of ATT and 72 
(59.5%) had a successful treatment outcome (Table 1). Dying during treatment was more frequent in TB uncon-
firmed patients compared to those confirmed (16 (35.6%) vs 12 (15.8%), p value < 0.001). Blood samples on D7 
and D60 were available for 118 and 101 patients, respectively.
All Rif susceptible patients started first-line intensive phase ATT (isoniazid, rifampicin, ethambutol and 
pyrazinamide) at D0 and the 4 Rif positive patients (detected through Xpert MTB/RIF®) started second-line 
treatment with kanamycin, ethionamide, levofloxacin, pyrazinamide, ethambutol and cycloserine.
IP 10 kinetics. At D0, 87 (68.5%) of the 127 patients had IP-10 concentrations >781 pg/ml; 23 (48.9%) of 47 
patients with clinically diagnosed TB and 16 (80.0%) of 80 bacteriologically confirmed cases had IP-10 > 781 pg/
ml (p < 0.0001 using Pearson’s Chi-Squared test with Yate’s continuity correction). Among bacteriologically con-
firmed cases, patients on antiretroviral therapy (ART) were less likely to have IP-10 > 1081 pg/ml at D0 than 
patients not on ART (31/44 (70.5%) vs 28/31 (90.3%), p = 0.039). There was no statistically significant association 
between the D0 IP-10 classification and sputum smear status, CD4 count or sex.
Figure 2 depicts the IP-10 kinetics on D0, D7 and D60. The majority of participants had a decline in IP-10 
which occurred during the first 7 days of ATT. The mean decline of all participants between D0 and D7 was 
1577 pg/dl. Bacteriologically confirmed cases were more likely to have high IP-10 levels at D0 and a steeper 
decline between D0 and D7 than clinically diagnosed cases (mean decline: 2282 vs 254 pg/dl for confirmed vs 
Figure 1. Treatment response classification algorithm used based on IP-10 Kinetics between D0 and D7.
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unconfirmed TB respectively; p = 0.002). No statistically significant declines between both groups were observed 
between D7 and D60 (486 vs 71 pg/dl for confirmed vs unconfirmed TB respectively, p value = 0.06).
Prediction of TB laboratory confirmation based on IP-10 kinetics during the first week of treatment. 
With regard to the predictive algorithm, 61 patients had an IP-10 decline >300 pg/ml between D0 and D7. The 
proportion of bacteriologically confirmed cases was significantly higher among those who had an IP-10 decline 
(>300 pg/ml) than patients without significant IP-10 changes between D0 and D7 (48/61 (78.7%) vs 29/57 
(50.9%), p = 0.002).
Among patients with no evidence of drug resistance, bacteriologically confirmed cases were 1.7 times more 
frequent among patients with IP-10 declines of >300 pg/ml in the first week than among patients with smaller 
IP-10 changes (38/51 (74.5%) vs 22/50 (44.0%) p = 0.002) (Table 2).
Prediction of IP-10 kinetics performance based on bacteriological confirmation at D0. 
Bacteriologically confirmed cases were more likely to have a decline of IP-10 levels >300 pg/ml between D0 - D7 
than clinically diagnosed cases (48/77 (62.3%) vs 13/41 (31.7%), p < 0.001). Similar results were obtained if only 
fully susceptible patients were included: 38/60 (63.3%) vs 13/41 (31.7%) for bacteriologically confirmed and clin-
ically diagnosed cases respectively, p = 0.001) (Table 3).
Cases with IP-10 decreases >300 pg/ml (D0 - D7) were less likely to have death as the reported treatment out-
come than patients with IP-10 differences <300 pg/ml (10/48 (20.8) vs 12/45 (26.7%), p value = 0.51). The same 
trend was observed if the analysis was restricted to bacteriologically confirmed cases (5/38 (13.2) vs 4/21 (19.0%), 
p-value = 0.34). However in both cases, this association was not statistically significant (Table 4).
Discussion
This study builds on previous research assessing the role of IP-10 in TB treatment monitoring and confirms 
that IP-10 is also a promising serum biomarker to assess treatment response during the first week of treatment 
in patients with HIV. We report that serum IP-10 levels are generally increased before TB treatment and that 
Characteristics n (%)
TB case
Clinically diagnosed 47 (37.0)
Bacteriologically confirmed 80 (63.0)
smear 39(48.8)
MGIT culture (MTB) 74(92.5)
Xpert 79(99.0)
Resistance pattern (n = 76)*
Resistant to rifampicin (Xpert) or MDR* 4 (5.2)
Resistant to isoniazid only 7 (9.2)
Resistant to isoniazid and pyrazinamide 1 (1.3)
Resistant to streptomycin only 4 (5.2)
Resistant to pyrazinamide only 2 (2.6)
Sex
Male 74 (58.3)
Female 53 (41.7)
CD4 counts/ml (n = 102)
<100 35 (34.3)
100-299 39 (38.2)
>300 28 (27.5)
On Antiretroviral Treatment
Yes 75(61.5)
No 47(38.5)
Age in years; mean (SD) 37.1 (10.1)
Treatment outcomes
Died 28(23.1)
Completed treatment 23(19.0)
Cured 49(40.5)
Failed 3(2.5)
Lost to follow up 13(10.7)
Not evaluated 5(4.1)
Table 1. Baseline characteristics of 127 patients participating in the study. Acronyms: SD: standard deviation: 
Rif: rifampicin; MDR: multidrug resistant. *One rifampicin-resistant case (through Xpert) was not confirmed 
with MGIT based drug susceptibility testing. One other case with rifampicin resistance was contaminated in 
MGIT-based drug susceptibility testing.
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increased levels are associated with bacteriologically confirmed TB. In our cohort of HIV-infected patients 
started on anti-tuberculosis treatment, IP-10 levels decreased during the early phases of treatment, as previously 
reported in HIV uninfected populations15,17,18,21. This study confirms that an IP-10 reduction >300 pg/ml in the 
first seven days of therapy is strongly associated with confirmed versus unconfirmed TB and that the absence of 
these changes is predictive of unconfirmed TB. Although IP-10 concentrations may reflect the bacteriological 
load in a patient, it is possible that a high proportion of clinically diagnosed patients did not have TB and were 
inappropriately treated, particularly as we used highly sensitive confirmation methods (both liquid culture and 
Xpert® MTB/RIF)29,30.
High IP-10 levels >1081 pg/ml on D0 as a single TB screening tool would have excluded 20% of confirmed 
TB cases, this performance is below what has been considered acceptable by a WHO panel5. This small but sig-
nificant proportion of confirmed TB cases without dramatically raised IP-10 levels has been observed in other 
studies15,21. Investigating to what extent these patients differ from those with raised IP-10 levels needs to be elu-
cidated. Among patients with a high IP-10 level at diagnosis, a limited or no decrease in IP-10 concentrations by 
D7 identifies patients who might be more likely to benefit from further diagnostic and clinical investigations. This 
approach may be especially valuable in settings with large proportions of patients with undiagnosed MDR-TB 
who would also be expected have a reduced/delayed IP-10 response to treatment.
Figure 2. Kinetics of IP-10 at three time points (D0, D7 and D60). N = 126.
IP-10 based 
classification
Bacteriological 
status at diagnosis
All cases
Excluding cases with any drug 
resistance to HRZE#
Total 
cases* n (%) p-value
Total 
cases n (%) p-value
Response to 
treatment
TB 
bacteriologically 
confirmed 61
48 78.7
0.002
51
38 74.5
0.002
TB clinically 
diagnosed 13 21.3 13 25.5
Poor response 
to treatment
TB 
bacteriologically 
confirmed 57
29 50.9
50
22 44.0
TB clinically 
diagnosed 28 49.1 28 56.0
Total 118 101
Table 2. Prediction of bacteriological status at diagnosis by IP-10 response between D0 and D7. *Some patients 
(n = 9) did not have D7 IP-10 data (including one Rif resistant case), thus were excluded in this table. #This 
analysis includes cases with streptomycin resistance and excludes 4 cases bacteriologically confirmed without 
MGIT-based drug susceptibility testing. H:Isoniazid; R: Rifampicin; Z: Pyrazinamide; E: Ethambutol.
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Our blinded prediction of bacteriological status based only on IP-10 kinetics between D0 and D7 was correct 
in almost two thirds of the cases, and this association was statistically significant. Our hypothesis was quite sim-
plistic since if IP-10 showed no response, we predicted it was from an unconfirmed patient or a drug-resistant 
case. However, even though we used a sensitive gold standard diagnostic we can be reasonably certain that a 
proportion of the clinically diagnosed patients in fact did not have TB2,3. Thus, we believe we present a minimum 
estimate of the performance of our predictive model and we would have been more accurate if there was a way 
of ascertaining the TB status among those who were clinically diagnosed. However, applying this algorithm to 
a population of TB presumptive cases who ultimately are diagnosed with another disease could further test our 
hypothesis. In addition, our hypothesis was that MDR patients would not show a decrease on IP-10 levels during 
the first week of treatment, but the number of MDR strains or Rif resistant strains in our sample was too low to 
test this assumption, and fact all of them received appropriate treatment. In addition, we do not know how the 
different levels of resistance or which specific drugs to which M. tuberculosis is resistant are necessary to affect the 
kinetics of IP-10. This was the reason why we conducted a subgroup analysis among those fully susceptible to first 
line drugs. However these results merely emphasize the need to assess IP-10 in settings with high prevalence of 
drug resistant TB, such as Eastern Europe.
Although those who showed a good response to treatment based in IP-10 kinetics between Day 0 and Day 
7 died less frequently during treatment than those with poor response to treatment, there was no evidence that 
IP-10 kinetics in the first week of treatment predicts death during treatment (p-value > 0.05). Probably, many 
factors contribute to death during TB treatment, beyond an initial active therapy. Unfortunately, we do not know 
the actual cause of death among study patients under treatment, which would have been very interesting for this 
specific analysis.
Bacteriological 
status at 
diagnosis*
All cases
Excluding any case with 
drug resistance to HRZE#
n % p value n % p value
Bacteriologically 
confirmed TB 
(n = 77)
Response to 
treatment (decline 
>300 pg/ml)
48 62.3 38 63.3
Poor response to 
treatment (decline 
<300 pg/ml)
16 20.8 13 21.7
Poor response to 
treatment (low IP-10 
at D0)
13 16.3 9 15.0
Clinically 
diagnosed TB 
(n = 41)
Response to 
treatment (decline 
>300 pg/ml)
13 31.7 <0.0021 13 31.7 0.0021
Poor response to 
treatment (decline 
<300 pg/ml)
24 58.5 <0.0012 24 58.5 <0.0012
Poor response to 
treatment (low IP-10 
at D0)
4 9.8 0.0123 4 9.8 0.0333
Total 118 101
Table 3. Prediction of treatment response based on IP-10 kinetics by laboratory confirmation status at D0. 
*Some patients did not have D7 IP-10 data (=9), thus were excluded in this table. #This analysis includes cases 
with streptomycin resistance and excludes 4 cases bacteriologically confirmed without MGIT-based drug 
susceptibility testing. H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol. P-values correspond to 
the statistical significance between bacteriological status at diagnosis and IP-10 response (in a binary form): 
1Response to treatment and Poor response to treatment (both “poor response” categories), 2Response to 
treatment and Poor response to treatment (decline <300 pg/ml); 3Response to treatment and Poor response to 
treatment (low IP-10 at D0).
Tuberculosis treatment response based on IP-10 Kinetics between D0 and D7
p-value
All cases
p-value
TB Confirmed cases
Response to 
treatment
Poor 
Response to 
treatment Total
Response to 
treatment
Poor 
Response 
to 
treatment
Totaln % n % n n % n %
Treatment Outcome Treatment success 38 79.17 33 73.33 71 0.51 33 86.84 17 81.0 50 0.34
Died 10 20.83 12 26.67 22 5 13.16 4 19.0 9
Total 48 45 93 38 100 21 100 59
Table 4. Association of treatment response based on IP-10 kinetics between day 0 and day 7 and treatment 
outcomes.
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In addition to the limited number of patients with drug resistance, our study had several other limitations. 
First, although the use of a commercially available ELISA kit (Becton Dickinson and Company, New Jersey, USA, 
- Human IP-10 ELISA Set. Cat. No. 550926) allowed us to perform this relatively large study onsite, it is different 
assay than that which was used in the earlier study21 we based our diagnostic algorithm on. This could mean that 
the cut offs used might not be exactly the same when using other commercially available assays31. The fact that 
similar conclusions can be reached using different assay formats is reassuring but may limit the generalizability of 
using those precise thresholds. In fact, it could be the case that the results we present are poorer than those that 
could be obtained with optimized cut off values for the assay used. Future head to head comparisons of different 
assays with same samples are needed to further validate or optimize the proposed cut offs.
Secondly, the ELISA kit and the serum dilutions measured resulted in a IP-10 detection limit of IP-10 limit 
of 780 pg/ml, thus some of the patients with an initial IP-10 level of <1081 pg/ml (allowing a decrease of 300 pg/
ml to be quantified) might have been classified as “non-responders” due to the initially low IP-10 levels, despite 
having higher IP-10 levels than the average serum values in adult populations32,33. Thirdly, in this study we were 
not able to closely follow up patients beyond their month 2 visit. More detailed follow up could have identified 
alternative diagnoses or comorbidities explaining the initial TB-like symptoms, and contributed to a better char-
acterization of the clinically diagnosed patients showing no response with regards to IP-10 kinetics. Lastly, our 
definition of good response was a decline of 300 pg/ml with an initial IP-10 level over 1081 pg/ml, based on a pre-
vious study by den Hertog et al.21. However, this threshold was established after analysis of only a limited number 
of patients and larger studies are needed to explore the use of alternative thresholds or alternative strategies (e.g. 
percent decrease). Sensitivity analysis of different thresholds could also be explored by combining datasets of 
individual similar studies.
In conclusion, this study confirms an association between a decrease in IP-10 levels during the first week of 
treatment in HIV positive patients and a bacteriological confirmation at diagnosis. Further work should explore 
the use of IP-10 kinetics in combination with other promising biomarkers to increase the sensitivity and identify 
the group of approximately 20% of patients who do not present with initially raised levels of circulating IP-10. 
This group of bacteriologically confirmed cases who do not present with significantly raised circulating IP-10 
warrant more detailed investigation. Additionally, similar studies in settings with high levels of drug resistance 
should be a priority, as biomarker kinetics may be able to identify patients with drug resistance on inappropriate 
therapy much more rapidly than is possible with microscopy or culture. The measurement of IP-10 in other sam-
ples, such as urine, should also be explored14. In summary, the correlation of this responsive easily measured bio-
marker13,21,34 with culture conversion or the identification of specific patient populations warrants further study.
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